Bioventus Inc.

NasdaqGS:BVS Stock Report

Market Cap: US$890.5m

Bioventus Future Growth

Future criteria checks 2/6

Bioventus is forecast to grow earnings and revenue by 17% and 6.5% per annum respectively while EPS is expected to grow by 16.2% per annum.

Key information

17.0%

Earnings growth rate

16.21%

EPS growth rate

Medical Equipment earnings growth16.1%
Revenue growth rate6.5%
Future return on equityn/a
Analyst coverage

Low

Last updated15 May 2026

Recent future growth updates

Analysis Article • Aug 09

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...

Recent updates

Narrative Update • May 19

BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price

Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).
Analysis Article • May 14

Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are

Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...
Narrative Update • May 01

BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside

Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.
Narrative Update • Apr 17

BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside

Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.
Narrative Update • Apr 03

BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside

Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.
Narrative Update • Mar 19

BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside

Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.
Narrative Update • Mar 05

BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential

Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.
Narrative Update • Feb 19

BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside

Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.
Narrative Update • Feb 05

BVS: Fine Tuned Assumptions Will Support Further Upside Potential

Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.
Narrative Update • Jan 22

BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside

Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.
Narrative Update • Jan 07

BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential

Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.
Narrative Update • Dec 20

BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential

Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).
Narrative Update • Dec 06

BVS: Earnings Guidance Will Support Continued Upside Potential In Shares

Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.
Seeking Alpha • Dec 02

Bioventus: A New Start

Summary Bioventus is regaining stability after a volatile period, with improving margins and organic sales growth driving renewed optimism. The company trades at compelling valuation multiples—below 2x sales, ~7x adjusted EBITDA, and ~11x adjusted earnings—supported by accelerating organic revenue growth. Recent refinancing is set to reduce annual interest costs by over $2 million, and net debt has declined to $280 million, lowering leverage to around 2.5x. With continued sales and margin growth, disciplined capital allocation could enable Bioventus shares to revisit the teens by 2026. Read the full article on Seeking Alpha
Analysis Article • Nov 26

Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Narrative Update • Nov 22

BVS: Earnings Guidance Is Expected To Drive Share Price Higher

Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.
Narrative Update • Nov 03

BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025

Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.
Narrative Update • Oct 20

Minimally Invasive Nonopioid Pain Management Will Expand With PNS

Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.
Narrative Update • Oct 05

Minimally Invasive Nonopioid Pain Management Will Expand With PNS

Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.
Analysis Article • Aug 14

We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative

NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...
Analysis Article • Aug 09

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...
User avatar
New Narrative • May 30

Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets

Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.
Analysis Article • May 07

Is Bioventus (NASDAQ:BVS) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Mar 08

Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues

Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...
Seeking Alpha • Jan 05

Bioventus: Amply Rewarded For Recent Progress

Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Aug 12

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 24

Bioventus: Bullish On Path To Profitability

Summary Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround. The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment including therapeutic injections for osteoarthritis. Shares are attractively priced ahead of the Q4 earnings report where we expect management to deliver positive 2024 guidance. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:BVS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028687471081053
12/31/20276463997955
12/31/20266063085855
3/28/202657628101103N/A
12/31/2025568237275N/A
9/27/2025564105356N/A
6/28/202556423436N/A
3/29/2025568-342425N/A
12/31/2024573-363739N/A
9/28/2024555-422830N/A
6/29/2024537-44811N/A
3/30/2024523-2227N/A
12/31/2023512-97815N/A
9/30/2023503-104010N/A
7/1/2023511-169818N/A
4/1/2023514-173-110N/A
12/31/2022512-104-25-14N/A
10/1/2022517-91-15-6N/A
7/2/2022497-19-46N/A
4/2/2022466-161120N/A
12/31/2021431-5923N/A
10/2/2021399-32935N/A
7/3/202137664046N/A
4/3/202132443136N/A
12/31/2020321165572N/A
9/26/2020320167167N/A
6/27/2020316126258N/A
3/28/2020339155554N/A
12/31/20193409N/A41N/A
12/31/2018319-1N/A45N/A
4/2/2016266-23N/A25N/A
12/31/2015254-38N/A19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BVS's forecast earnings growth (17% per year) is above the savings rate (3.5%).

Earnings vs Market: BVS's earnings (17% per year) are forecast to grow faster than the US market (16.8% per year).

High Growth Earnings: BVS's earnings are forecast to grow, but not significantly.

Revenue vs Market: BVS's revenue (6.5% per year) is forecast to grow slower than the US market (11.6% per year).

High Growth Revenue: BVS's revenue (6.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BVS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 23:01
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/28
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bioventus Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Kyle RoseCanaccord Genuity
Caitlin CroninCanaccord Genuity